The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Bausch Health Companies Inc. (BHC) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.17, or 1.84%, to $9.39. The Bausch Health Companies Inc. has recorded 30,263 volume in the after hours trading session.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
The company is listed on the NYSE and operates within the Drug Manufacturers – Specialty & Generic industry segment. At the end of the last regular session, the stock closed at $9.22 and fluctuated between $9.45 as its day high and $9.11 as its day low. The current market capitalization of Bausch Health Companies Inc. is $3.43B. A total of 3.67 million shares were traded on the day, compared to an average of 6.06M shares.
In the most recent transaction, Carson Seana sold 292 shares of BHC for 9.32 per share on Feb 28. After the transaction, the EVP, General Counsel now owns 359,185 company shares. In a previous transaction on Jun 01, Bausch Health Companies Inc. sold 4,550,357 shares at 17.05 per share. BHC shares that 10% Owner owns now total 310,449,643.
Among the insiders who sold shares, Bausch Health Companies Inc. disposed of 35,000,000 shares on May 10 at a per-share price of $17.05. This resulted in the 10% Owner holding 315,000,000 shares of BHC after the transaction. In another insider transaction, Spurr Robert sold 1,595 shares at $22.19 per share on Apr 14. Company shares held by the U.S. President-Pharma Business now total 90,506.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for BHC in the last 3 months, the mean price target is $9.00 with high estimates of $10.00 and low estimates of $7.00. In terms of 52-week highs and lows, BHC has a high of $24.30 and a low of $4.00.
As of this writing, BHC has an earnings estimate of $0.91 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $1.11 per share and a lower estimate of $0.73. The company reported an EPS of $0.56 in the last quarter, which was -37.10% lower than expectations of $0.89.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 8 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BHC is Overweight with a score of 3.14. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 6 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.